Turn Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $319.92M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | After market close | – | $-0.20 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | – | $-0.07 | – |
Press releases
Announcements Turn Therapeutics filed with the SEC
INVESTOR PRESENTATION, DATED OCTOBER 6, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 10, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 9, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED AUGUST 12, 2026
Results of operations · EX-99.1 to Form 8-K
INVESTOR PRESENTATION, DATED JULY 28, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JULY 7. 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
INVESTOR PRESENTATION, DATED JULY 7, 2026
Regulation FD disclosure · EX-99.2 to Form 8-K
INVESTOR PRESENTATION, DATED JUNE 3, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JUNE 1, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED MAY 27, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED MAY 19, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED MAY 18, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED MAY 11, 2026
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE, DATED MARCH 31, 2026
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE, DATED MARCH 24, 2026
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED FEBRUARY 17, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED FEBRUARY 9, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
INVESTOR PRESENTATION DATED FEBRUARY 9, 2026
Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE, DATED JANUARY 12, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JANUARY 7, 2026
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
INVESTOR PRESENTATION, DATED JANUARY 7, 2026
Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE, DATED NOVEMBER 13, 2025
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE, DATED NOVEMBER 11, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED NOVEMBER 11, 2025
Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE, DATED NOVEMBER 4, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Turn Therapeutics Enters Global Supply, Development,
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones
Regulation FD disclosure · EX-99.1 to Form 8-K